- Zinc L-Carnosine, a pharmaceutical in Japan for over 20 years, hosts a large body of research supporting its efficacy in dealing with canker sores (mouth ulcers), oral discomfort, and establishing a healthy mucosal lining in the mouth.
- The double-blind, placebo controlled human clinicals examined cancer patients undergoing radiation therapy. One side effect of this therapy is oral mucositis which is a more extreme form of a mouth ulcers. The Zinc L-Carnosine groups in each study always had lower grade oral mucositis symptoms compared to the control groups.
- Other studies relating to time efficacy of the ingredient display relief in 3-4 days.
- Preventive and therapeutic effects of polaprezinc suspension on oral mucosal injury
- Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplanation
- Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc l-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy
- Effect of polaprezinc on oral mucositis, irradiation period, and time to discharge in patients with head and neck cancer
- Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients
- A zinc-containing compound, Polaprezinc, is effective for patients woth taste disorders: randomized, double-blind, placebo-controlled, multi-center study
- Prevention of radiation esophagitis by polaprezinc (zinc L-carnosine) in patients with non-small cell lung cancer who received chemoradiotherapy